14 Dec 2023
ZERO Biotech embarked on a highly anticipated site visit to the Nuclear Technology Application (Isotope) Industrial Park in Haiyan, Zhejiang. This visit marks an important step in ZERO Biotech's commitment to advancing its research and development capabilities in the field of nuclear medicine. This visit underscores ZERO Biotech's determination to expand its research and development capabilities in nuclear medicine within the Asian region.
The Nuclear Technology Application (Isotope) Industrial Park in Haiyan, Zhejiang, is recognized as a hub for cutting-edge nuclear technology research and innovation. The park fosters collaboration among industry leaders, academic institutions, and regulatory bodies, creating a conducive environment for scientific advancements in nuclear technology.
During the site visit, ZERO Biotech's executives had the opportunity to explore the state-of-the-art facilities and engage in insightful discussions with experts from the nuclear medicine field. The visit offered a unique chance to witness the park's advanced infrastructure, research laboratories, and surrounding supporting facilities, which are integral to the development and production of radiopharmaceuticals.
Earlier this month, Swiss pharmaceutical company Novartis has announced it would invest more than 600 million yuan ($84 million) in a new radiopharmaceutical production facility in the same region. It demonstrates the strategic location and value of Haiyan, being located at the heart of the city cluster of the Yangtze River Delta region.
Radiopharmaceuticals play a vital role in modern medicine, enabling precise diagnosis and targeted treatment of various diseases, including cancer therapies. With its focus on nuclear technology, ZERO Biotech is committed to pushing the boundaries of radiopharmaceutical development and improving patient outcomes. The site visit to the Industrial Park in Haiyan signifies a strategic step forward in realizing these objectives and further establishing ZERO Biotech as a key player in the Asian nuclear medicine landscape.
